Is a delay in the introduction of human papillomavirus-based cervical screening affordable?

ABSTRACT:

Objective

It often takes considerable time for sufficient evidence to accumulate to support implementation of new methods in routine screening. Where national screening programmes are already effective, switching to a more sensitive screening test may not be a priority. Although risk associated with overly rapid implementation exists, postponement is also associated with a (to date unquantified) missed opportunity to prevent deaths. This risk tends not to be addressed where effective screening methods are already in use. We here estimate the monetary value of a one-year delay in replacing cytology cervical screening with human papillomavirus testing.

Methods

Using a previously validated model, we calculated the number of incident and fatal cervical cancers that would be diag

SUBMITTER: Castanon A 

PROVIDER: S-EPMC6376595 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature